171 related articles for article (PubMed ID: 16532026)
1. Negative cell cycle regulator 14-3-3sigma stabilizes p27 Kip1 by inhibiting the activity of PKB/Akt.
Yang H; Zhang Y; Zhao R; Wen YY; Fournier K; Wu HB; Yang HY; Diaz J; Laronga C; Lee MH
Oncogene; 2006 Aug; 25(33):4585-94. PubMed ID: 16532026
[TBL] [Abstract][Full Text] [Related]
2. 14-3-3sigma, a p53 regulator, suppresses tumor growth of nasopharyngeal carcinoma.
Yang H; Zhao R; Lee MH
Mol Cancer Ther; 2006 Feb; 5(2):253-60. PubMed ID: 16505098
[TBL] [Abstract][Full Text] [Related]
3. DNA damage-induced protein 14-3-3 sigma inhibits protein kinase B/Akt activation and suppresses Akt-activated cancer.
Yang H; Wen YY; Zhao R; Lin YL; Fournier K; Yang HY; Qiu Y; Diaz J; Laronga C; Lee MH
Cancer Res; 2006 Mar; 66(6):3096-105. PubMed ID: 16540659
[TBL] [Abstract][Full Text] [Related]
4. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer.
Viglietto G; Motti ML; Bruni P; Melillo RM; D'Alessio A; Califano D; Vinci F; Chiappetta G; Tsichlis P; Bellacosa A; Fusco A; Santoro M
Nat Med; 2002 Oct; 8(10):1136-44. PubMed ID: 12244303
[TBL] [Abstract][Full Text] [Related]
5. PI3K/AKT pathway-mediated regulation of p27(Kip1) is associated with cell cycle arrest and apoptosis in cervical cancer.
Prasad SB; Yadav SS; Das M; Modi A; Kumari S; Pandey LK; Singh S; Pradhan S; Narayan G
Cell Oncol (Dordr); 2015 Jun; 38(3):215-25. PubMed ID: 25821107
[TBL] [Abstract][Full Text] [Related]
6. Constitutively active FOXO4 inhibits Akt activity, regulates p27 Kip1 stability, and suppresses HER2-mediated tumorigenicity.
Yang H; Zhao R; Yang HY; Lee MH
Oncogene; 2005 Mar; 24(11):1924-35. PubMed ID: 15688030
[TBL] [Abstract][Full Text] [Related]
7. Reduction of cytosolic p27(Kip1) inhibits cancer cell motility, survival, and tumorigenicity.
Wu FY; Wang SE; Sanders ME; Shin I; Rojo F; Baselga J; Arteaga CL
Cancer Res; 2006 Feb; 66(4):2162-72. PubMed ID: 16489017
[TBL] [Abstract][Full Text] [Related]
8. Antitumoral activity of lenalidomide in in vitro and in vivo models of mantle cell lymphoma involves the destabilization of cyclin D1/p27KIP1 complexes.
Moros A; Bustany S; Cahu J; Saborit-Villarroya I; Martínez A; Colomer D; Sola B; Roué G
Clin Cancer Res; 2014 Jan; 20(2):393-403. PubMed ID: 24178620
[TBL] [Abstract][Full Text] [Related]
9. Akt-dependent T198 phosphorylation of cyclin-dependent kinase inhibitor p27kip1 in breast cancer.
Motti ML; De Marco C; Califano D; Fusco A; Viglietto G
Cell Cycle; 2004 Aug; 3(8):1074-80. PubMed ID: 15280662
[TBL] [Abstract][Full Text] [Related]
10. Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels.
Morishita D; Katayama R; Sekimizu K; Tsuruo T; Fujita N
Cancer Res; 2008 Jul; 68(13):5076-85. PubMed ID: 18593906
[TBL] [Abstract][Full Text] [Related]
11. miR-221 confers lapatinib resistance by negatively regulating p27
Huynh TK; Huang CH; Chen JY; Yao JH; Yang YS; Wei YL; Chen HF; Chen CH; Tu CY; Hsu YM; Liu LC; Huang WC
Cancer Sci; 2021 Oct; 112(10):4234-4245. PubMed ID: 34382727
[TBL] [Abstract][Full Text] [Related]
12. DFMO/eflornithine inhibits migration and invasion downstream of MYCN and involves p27Kip1 activity in neuroblastoma.
Koomoa DL; Geerts D; Lange I; Koster J; Pegg AE; Feith DJ; Bachmann AS
Int J Oncol; 2013 Apr; 42(4):1219-28. PubMed ID: 23440295
[TBL] [Abstract][Full Text] [Related]
13. YAP promotes the proliferation of neuroblastoma cells through decreasing the nuclear location of p27
Shen X; Xu X; Xie C; Liu H; Yang D; Zhang J; Wu Q; Feng W; Wang L; Du L; Xuan L; Meng C; Zhang H; Wang W; Wang Y; Xie T; Huang Z
Cell Prolif; 2020 Feb; 53(2):e12734. PubMed ID: 31863533
[TBL] [Abstract][Full Text] [Related]
14. Deregulated expression of p27(Kip1) in human breast cancers.
Sgambato A; Zhang YJ; Arber N; Hibshoosh H; Doki Y; Ciaparrone M; Santella RM; Cittadini A; Weinstein IB
Clin Cancer Res; 1997 Oct; 3(10):1879-87. PubMed ID: 9815577
[TBL] [Abstract][Full Text] [Related]
15. Id-1 activates Akt-mediated Wnt signaling and p27(Kip1) phosphorylation through PTEN inhibition.
Lee JY; Kang MB; Jang SH; Qian T; Kim HJ; Kim CH; Kim Y; Kong G
Oncogene; 2009 Feb; 28(6):824-31. PubMed ID: 19079342
[TBL] [Abstract][Full Text] [Related]
16. Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression.
Graff JR; Konicek BW; McNulty AM; Wang Z; Houck K; Allen S; Paul JD; Hbaiu A; Goode RG; Sandusky GE; Vessella RL; Neubauer BL
J Biol Chem; 2000 Aug; 275(32):24500-5. PubMed ID: 10827191
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic and proteolytic inactivation of 14-3-3sigma in breast and prostate cancers.
Horie-Inoue K; Inoue S
Semin Cancer Biol; 2006 Jun; 16(3):235-9. PubMed ID: 16682214
[TBL] [Abstract][Full Text] [Related]
18. Prodigiosin down-regulates SKP2 to induce p27(KIP1) stabilization and antiproliferation in human lung adenocarcinoma cells.
Hsieh HY; Shieh JJ; Chen CJ; Pan MY; Yang SY; Lin SC; Chang JS; Lee AY; Chang CC
Br J Pharmacol; 2012 Aug; 166(7):2095-108. PubMed ID: 22372491
[TBL] [Abstract][Full Text] [Related]
19. RAD 001 (everolimus) prevents mTOR and Akt late re-activation in response to imatinib in chronic myeloid leukemia.
Mancini M; Petta S; Martinelli G; Barbieri E; Santucci MA
J Cell Biochem; 2010 Feb; 109(2):320-8. PubMed ID: 20014066
[TBL] [Abstract][Full Text] [Related]
20. TRIP6 regulates p27 KIP1 to promote tumorigenesis.
Lin VT; Lin VY; Lai YJ; Chen CS; Liu K; Lin WC; Lin FT
Mol Cell Biol; 2013 Apr; 33(7):1394-409. PubMed ID: 23339869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
